Cureus · 2026
The Effect of Bevacizumab Therapy on Reducing Erythrocyte Transfusion Requirements and Preventing Iron Deficiency in Patients With Hereditary Hemorrhagic Telangiectasia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aydın Öznur, Köseoğlu Fatoş Dilan, Sayın Selim, Gözden Hilmi Erdem, Şahin Onur, Ataş Ünal, Kürekci Derya Deniz, Aktimur Sude Hatun, Aylı Meltem, Turgut Mehmet, Güven Serkan
Аннотация
OBJECTIVE: This multicenter retrospective cohort study aimed to evaluate the association between intravenous (IV) bevacizumab therapy and iron-related parameters and transfusion burden in patients with hereditary hemorrhagic telangiectasia (HHT) in Turkey.
METHODS: Thirty-five genetically or clinically confirmed HHT patients from tertiary centers were included. Patients receiving IV bevacizumab (n=15) were compared with those without bevacizumab exposure (n=20). Longitudinal hematologic parameters, annual IV iron dose, erythrocyte suspension (ES) transfusion volume, and bleeding frequency were recorded. In the bevacizumab group, pre- and post-treatment values were compared.
RESULTS: Before treatment, patients who subsequently received bevacizumab had higher ES transfusion requirements than untreated patients (median 6 vs. 2 units; p=0.029). After bevacizumab therapy, IV iron requirement decreased (median 5000 mg to 2000 mg; p=0.005) and ES transfusion burden declined (median 6 to 0 units; p=0.002). Compared with the non-bevacizumab group, treated patients had higher final hemoglobin (p=0.042) and ferritin levels (p=0.048), while transferrin saturation was higher in the untreated group (p=0.047).
CONCLUSION: In this multicenter retrospective cohort, IV bevacizumab therapy was associated with improved iron parameters and reduced transfusion requirements in patients with HHT-related bleeding.
METHODS: Thirty-five genetically or clinically confirmed HHT patients from tertiary centers were included. Patients receiving IV bevacizumab (n=15) were compared with those without bevacizumab exposure (n=20). Longitudinal hematologic parameters, annual IV iron dose, erythrocyte suspension (ES) transfusion volume, and bleeding frequency were recorded. In the bevacizumab group, pre- and post-treatment values were compared.
RESULTS: Before treatment, patients who subsequently received bevacizumab had higher ES transfusion requirements than untreated patients (median 6 vs. 2 units; p=0.029). After bevacizumab therapy, IV iron requirement decreased (median 5000 mg to 2000 mg; p=0.005) and ES transfusion burden declined (median 6 to 0 units; p=0.002). Compared with the non-bevacizumab group, treated patients had higher final hemoglobin (p=0.042) and ferritin levels (p=0.048), while transferrin saturation was higher in the untreated group (p=0.047).
CONCLUSION: In this multicenter retrospective cohort, IV bevacizumab therapy was associated with improved iron parameters and reduced transfusion requirements in patients with HHT-related bleeding.